Home›Stock Screener›Corona Remedies

Corona Remedies Share Price Today | Stock Price & Corona Remedies Share Screener

CORONA Pharmaceuticals & Biotechnology
Live Share Price NSE
₹2256.20
▼ -19.40 (-0.85%)
2026-11-18 00:00:00
Live Share Price BSE
₹2257.15
▼ -18.20 (-0.80%)
2026-11-18 00:00:00

As of November 18, 2026, the live Corona Remedies share price (NSE: CORONA) is ₹2,256.20 on NSE and ₹2,257.15 on BSE, down 0.85% from the previous close, with shares trading between ₹2,250.00 and ₹2,308.40 in today's trading session, and a 52-week range of ₹1,347.70–₹2,539.40. Track Corona Remedies market worth to gauge the company's total market size. Use the Corona Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Corona Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹444 and net income of ₹60, with EBITDA of ₹99, an operating margin of 22.0% and a profit margin of 13.5%.

Corona Remedies Market Cap ₹13,917.60 Cr.
CORONA P/E Ratio (TTM) 67.20
Corona Remedies P/B Ratio 17.28
EPS (TTM) ₹30.27
Dividend Yield 0.44%
Debt to Equity 0.19
CORONA 52 Week High ₹2539.40
Corona Remedies 52 Week Low ₹1347.70
Operating Margin 22.00%
Profit Margin 13.51%
CORONA Revenue (TTM) ₹444.00
EBITDA ₹99.00
Net Income ₹60.00
Total Assets ₹1,205.00
Total Equity ₹747.00

Corona Remedies Share Price Chart

Track the current stock price of Corona Remedies with an interactive chart. Analyse CORONA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Corona Remedies stock quote in one place.

The quote of ₹2,256.20 sits between the 52-week low of ₹1,347.70 and the 52-week high of ₹2,539.40, and the latest session moved -0.85% from the previous close.

Corona Remedies Company Profile - Fundamental Screener

Screen Corona Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CORONA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE02ZQ01018.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE02ZQ01018

Corona Remedies Balance Sheet Screener

Screen CORONA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,205, up from ₹930 in 2025.

Latest statistics put total assets at ₹1,205 and shareholder funds at ₹747, with a leverage ratio of 0.19.

Item 2026 2025 2024 2023

Assets

Total Assets 1,205 930 831 595
Current Assets 0 0 0 0
Fixed Assets 554 370 384 185

Liabilities

Total Liabilities 0 0 0 0
Current Liabilities 97 84 126 49
Non-Current Liabilities 0 0 0 0

Shareholders' Equity

Total Equity 747 606 480 409
Share Capital 61 61 61 61
Reserves & Surplus 686 545 419 347

Corona Remedies Income Statement Screener - Profit & Revenue Analysis

Screen Corona Remedies income statement and profit fundamentals. Analyze CORONA quarterly results. Corona Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹444 and net profit was ₹60, equal to earnings per unit of ₹9.86, at an operating margin of 22%.

In that period expenses were ₹345, interest cost ₹3 and tax ₹20. The next period listed, 2026-Jun, shows revenue of ₹426 and net profit of ₹60.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun

Revenue and Expenses

Revenue 444 426 358 345 364 349 295 299 316 293
Expenses 345 329 291 278 283 277 240 228 247 242

Operating Costs and Margins

EBITDA 99 96 66 66 81 72 56 70 69 51
Operating Profit % 22.00% 22.00% 18.00% 19.00% 22.00% 20.00% 18.00% 23.00% 21.00% 17.00%
Depreciation 15 13 10 9 9 9 10 10 9 8
Interest 3 3 1 2 2 2 2 2 3 3

Profit and Earnings

Profit Before Tax 81 80 55 55 70 61 44 58 57 39
Tax 20 20 9 14 18 15 12 13 14 9
Net Profit 60 60 45 41 52 46 32 45 43 30
EPS 9.86 9.83 7.41 6.75 8.55 7.55 5.16 7.35 7.03 4.90

Corona Remedies Cash Flow Screener - Liquidity Fundamentals

Screen CORONA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹230, and net cash flow was an outflow of ₹1.

Over the same period, investing activities used ₹256 and financing activities provided ₹25.

Item 2026-March 2025-March 2024-March 2023-March

Cash from Operations and Investing

Operating Activities 230 191 157 103
Investing Activities -256 -84 -267 -50

Financing and Net Cash

Financing Activities 25 -107 99 -45
Net Cash Flow -1 0 -11 8

Corona Remedies Shareholding Pattern Screener

See Corona Remedies shareholding pattern with promoter, FII, and DII holdings. Check Corona Remedies promoter holding and ownership changes for CORONA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 69.00%, foreign institutions 4.21%, domestic institutions 16.45% and the public 1.03%, spread across 21,098 shareholders.

The shareholder count was 21,098 in 2026-Sept, compared with 20,185 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Apr

Promoter Holding

Promoter Holding 69.00% 69.00% 69.00% 69.00% 72.50%

Institutional Investors

FII Holding 4.21% 3.63% 2.25% 1.84% 0.00%
DII Holding 16.45% 12.90% 7.02% 6.76% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 1.03% 0.89% 0.77% 1.36% 0.00%
Other Holding 9.31% 13.58% 20.97% 21.05% 27.50%
Shareholder Count 21,098 20,185 19,609 9 9

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Corona Remedies. Corona Remedies dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹10.00 per unit for 2026-March, a yield of 0.44%, compared with ₹7.31 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹10.00, ₹7.31 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹10.00 0.44%
2025-March ₹7.31 0.47%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Corona Remedies Stock Index Membership - Nifty & Sensex

See which indices include Corona Remedies stock. Check CORONA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Corona Remedies is not part of any tracked indices.
Only major market indices are tracked in our system.

Corona Remedies Market Events Screener - Corporate Actions

Get Corona Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Corona Remedies stock events that may affect CORONA share price, along with derivatives, futures and options activity and sector gainers.

7 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 30, 2026, with a record date of October 30, 2026.

It is followed by Quarterly Result Announcement dated July 31, 2026 and Annual General Meeting dated July 9, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-30 2026-10-30 Quarterly Result Announcement NA 8.39%
2026-07-31 2026-07-31 Quarterly Result Announcement NA 1.27%
2026-07-09 2026-07-09 Annual General Meeting NA 14.52%
2026-06-19 2026-06-19 Dividend ₹ 10.00 /share 7.04%
2026-05-11 2026-05-11 Quarterly Result Announcement NA 1.36%
2026-02-02 2026-02-02 Quarterly Result Announcement NA 3.06%
2026-01-02 2026-01-02 Quarterly Result Announcement NA 4.10%

Corona Remedies Competitors Screener - Peer Stocks Comparison

Screen CORONA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,998 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 84.70 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 94.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.90 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 42.00 35,059 3.90% 4,158 71.26
Cipla 112,131 39.20 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.50 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.90 34,145 5.56% 3,503 60.39
Lupin 89,172 17.10 29,039 26.75% 5,356 39.39

Corona Remedies Company Announcements - News & Reports Screener

Screen CORONA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 19, 2026.

The next most recent announcements are dated November 10, 2026 and November 5, 2026.

Date Update Actions
2026-11-19 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-05 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-03 Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 -
2026-11-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-31 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-30 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-30 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-30 Unaudited Financial Results Along With The Limited Review Reports For Second Quarter And Half Year Ended September 30 2026 -
2026-10-30 Board Meeting Outcome for Outcome Of Board Meeting -
2026-10-22 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-22 Intimation Regarding Receipt Of GMP Compliance Certification From Brazilian Health Regulatory Agency ANVISA Brazil -
2026-10-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-16 Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Second Quarter And Half Year Ended On September 30 2026 -
2026-10-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-28 Closure of Trading Window -
2026-09-19 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-09-19 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹2,256.20, within a 52-week range of ₹1,347.70 to ₹2,539.40. The P/E ratio is 67.20 and the P/B ratio is 17.28, with earnings per unit of ₹30.27. Market capitalisation stands at ₹13,917.60 Cr and the dividend yield is 0.44%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 4 balance sheet periods, 10 income statement periods, 4 cash flow years and 5 shareholding periods. Information is provided for research and is not investment advice.